Connect with us

Featured

Non-hallucinogenic Neuroplastogens Enter First-in-Human Trials 

Published

on


For years, researchers have been looking for ways to harness the medical benefits of psychedelics, but without the hallucinations. Some neuroscientists even believe that the drugs’ mental-health benefits don’t come from tripping at all. Now, for the first time, researchers have developed psychedelic-inspired drugs that to bring on neuroplastic effects without producing a trip – a new breed of neuroplastogens. 

Neuroplasticity explained 

Neural plasticity describes the brain’s ability to change, adapt, and form new connections in response to various stimuli. It’s a vital aspect of healthy brain function, and as such, essential to the way we humans function in our day-to-day lives. Situations in which the brain demonstrates neuroplasticity include learning a new skill such a subject in school or a new language, practicing music, memorizing directions in a new city, and working on puzzles and memory games. It can also occur when a person loses a sense, such as hearing or sight, and their other senses start to overcompensate for the lost one.  

Many neurological and psychiatric ailments stem from a lack of neuroplasticity in the brain, which leads to poorly adaptive behavioral responses. Anxiety, depression, and substance abuse are common in people whose brains are unable to strengthen these beneficial circuits. Developing and maintaining neuroplasticity is crucial in promoting recovery from these brain and mood disorders that a large percentage of the adult population struggle with.  

Juvenile brains exhibit remarkable neuroplasticity, with both the ability to learn new things as well as the brain being able to quickly mend damaged circuits. But as we grow older, our brains become less plastic and we’re more prone to getting stuck in negative thought and behavioral patterns. This is why external intervention, often in the form of hallucinogenic drugs, is sometimes necessary to repair those broken connections and pathways.  

The science of neuroplastogens 

Neuroplastogens, also known as psychoplastogens, are a group of small-molecule drugs that are capable of producing rapid and long-lasting effects on both neural structure and function. Many are so potent that they are known to produce the desired therapeutic effects after only a single session. As such, neuroplastogens are quickly becoming the go-to option for treating these neurological disorders.  

Typically, hallucinogenic drugs like psilocybin and LSD, or dissociatives like ketamine and MDMA, are the gold-standard when it comes to improving neuroplasticity. Recently approved second-generation psychedelics like Spravato and COMP360 work via the same mechanisms. And as incredible as these substances may be, the problem is that not all patients have the time or desire for a psychedelic trip.  

A huge number of prospective consumers would prefer to reap the therapeutic benefits of these drugs, without the high. Not to mention, for reasons of liability, when doctors prescribe hallucinogens, the patient needs to be strictly monitored for the duration of their trip, which adds another layer of complexity (as well as higher costs) to the treatment process involving these drugs.  

That being said, there is a growing demand for neuroplastogens that are capable of promoting circuit-based plasticity in specific locations of the brain, without unwanted side effects (hallucinations). To meet this unfulfilled need, researchers are exploring the different ways that psychedelics can rewire key areas of the brain, should the psychedelic properties be excluded.  

For example, several studies show that ketamine can improve overall mood in humans, even if it’s administered when patients are unconscious. This means that patients who missed out on knowingly feeling ketamine’s dissociative effects, because they were not awake for them, still felt happier and less anxious after their operations – which suggests that you don’t need to consciously experience the high in order to benefit medicinally from the drugs.  

How do they work? 

Just like standard psychedelic drugs, these non-hallucinogenic neuroplastogens stimulate the same serotonin receptors, mainly 5-HT2A. When activated, the brain then produces a compound known as brain-derived neurotropic factor (BDNF), which functions as a sort of “brain fertilizer”, that promotes neural growth and survival. While activation of 5-HT2A is often associated with sensory hallucinations, this is not always the case. Different drugs bind to and activate receptors in a variety of ways, which results in very different effects. The focus of non-hallucinogenic psychoplastogens is to activate 5-HT2A serotonin receptors in a way that does not induce a trip.  

Some of these trip-free psychedelics are relatively new, like one that was synthesized two years ago (study published January 2022) by a team of Chinese researchers. The drug works by imitating the mechanisms of lisuride, an analog of LSD, as well as psilocin, the compound that our bodies convert psilocybin from mushrooms into. The drug does not have a name yet, just a serial number, IHCH-7113, and it’s currently undergoing animal trials.  

Per the study: “Here, we present structures of 5-HT2AR complexed with the psychedelic drugs psilocin (the active metabolite of psilocybin) and d-lysergic acid diethylamide (LSD), as well as the endogenous neurotransmitter serotonin and the nonhallucinogenic psychedelic analog lisuride. Serotonin and psilocin display a second binding mode in addition to the canonical mode, which enabled the design of the psychedelic IHCH-7113 (a substructure of antipsychotic lumateperone) and several 5-HT2AR β-arrestin–biased agonists that displayed antidepressant-like activity in mice but without hallucinogenic effects.” 

Other non-hallucinogenic neuroplastogens, although not widely used, have existed for decades. For example, a compound known as 2-Br-LSD (an analog of LSD), was first synthesized in 1957 by Albert Hofmann, the Swiss chemist who created LSD. Renewed interest in this compound has led to new studies, which found that 2-Br-LSD can effectively relieve anxious and depressive behavior in mice, but without twitching and other actions that are common when hallucinations occur. Now, several decades after its initial discovery, a Canadian company, Betterlife Pharma, is planning on conducting the first in-human trials using this trip-free psychedelic. 

Are hallucinations just the side-effect? Or something more? 

For those of us who truly believe in the healing power of psychedelics, hearing people who have likely never used them talk about how much better these drugs would be without hallucinations… well, it can be pretty annoying, to say the least. Many people who have participated in a psychedelic trip describe it as one of the most meaningful and educational experiences of their lives. Not to mention, several studies on psilocybin concluded that the intensity of the trip had a direct correlation on the magnitude and longevity of the therapeutic effects.  

Now let’s circle back to those studies about ketamine. Despite people feeling happier after ketamine administration even when they didn’t trip out, there are some questions there that remain unanswered. Comparatively, would the antidepressant effects have been stronger had they felt the hallucinogenic effects? How long did the positive effects last after their surgeries, in contrast to patients who experience the drugs in their full scope?  

And what about microdosing? Those who take subtherapeutic doses of psychedelic drugs claim to experience many of the neurological benefits – better mood, enhanced creativity, improved focus, and so on – even though the doses they are taking are so low they don’t feel a “high” or experience any sensory hallucinations. However, there are few studies to back up these sentiments, and some people don’t do well with small doses. I personally get very anxious and uneasy when I take low doses of psilocybin, compared to happy, positive highs when I use larger doses.  

So, while technically, yes, the hallucinations are a side effect, anyone who has used psychedelics in a meaningful and serious way can attest to the fact that visuals and other sensory feelings are informative and eye-opening in an extremely powerful way. Are they everything these products have to offer? No. Can people benefit from using these drugs without tripping? Absolutely. But are they missing out on a very important piece of the puzzle? Probably so.  

Final thoughts 

Like most aspects of this industry, more studies need to be done in order to determine how much we are really missing when we remove the trip from psychedelics. Non-hallucinogenic neuroplastogens certainly have an important place in wellness and pharma, as they will expose an entirely new population of mental health patients to the benefits of psychoplastogenic drugs. But which will reign superior? New age neuroplastogens with no hallucinogenic side effects? Or classic entheogens that help transport your senses and your entire being to transcendent new heights? Only time and more research will tell.  

Hello readers. We’re happy to have you with us at Cannadelics.com; a news source here to bring you the best in independent reporting for the growing cannabis and hallucinogen fields. Join us frequently to stay on top of everything, and subscribe to our Cannadelics Weekly Newsletter, for updates straight to your email. Check out some awesome promos for cannabis buds, smoking devices and equipment like vapes, edibles, cannabinoid compounds, amanita mushroom products, and a whole bunch more. Let’s all get stoned together!



Source link

Continue Reading

Cannabis

Mixed Messages From The Feds About Cannabis

Published

on

By


The federal administration is all over the board around fed cannabis policy…and millions of patients are worried.

The industry employees over 440,000 workers at all lives and is driven in a large part by mom and pop businesses.  Millions use medical marijuana for health issues ranging from chronic pain to sleep.  But there are mixed messages from the feds about cannabis, and people are very worried. The federal government’s stance on marijuana has become increasingly complex, as recent developments show conflicting approaches to the drug’s potential benefits and risks. On one hand, there’s a push for research into medical marijuana for veterans, while on the other, a campaign against cannabis use is being launched.

RELATED: Music Is A Turn On Like Sex And Marijuana

The juxtaposition of initiatives highlights the federal government’s inconsistent approach to marijuana policy. While some departments are exploring the potential benefits of cannabis, others are actively working to discourage its use. This dichotomy is further exemplified by ongoing legislative efforts. For instance, Rep. Brian Mast (R-FL) has reintroduced the Veterans Equal Access Act, which would allow VA doctors to recommend medical marijuana to patients in states where it’s legal. Meanwhile, documents from an ongoing lawsuit suggest that the DEA may have weighted the marijuana rescheduling process to ensure rejection of moving the drug from Schedule 1 to Schedule 3.

Photo by yavdat/Getty Images

The Department of Defense (DOD) has allocated nearly $10 million in funding for research into the therapeutic potential of MDMA for active-duty military members. This initiative, driven by congressional efforts, aims to explore MDMA’s effectiveness in treating conditions such as post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Rep. Morgan Luttrell (R-TX) expressed pride in this development, stating that it could be a “game-changer” for service members battling these combat-related injuries.

Additionally, a bipartisan effort in Congress has been pushing for VA research on medical marijuana for PTSD and other conditions affecting veterans. The VA Medicinal Cannabis Research Act, introduced in both the Senate and House, would mandate studies on how cannabis affects the use of addictive medications and impacts various health outcomes for veterans.

RELATED: The Science Behind Why Music Sounds So Much Better When You’re High

In stark contrast to these research initiatives, the Drug Enforcement Administration (DEA) has partnered with an anti-cannabis nonprofit to launch a social media campaign targeting young people. The campaign, set to run ahead of April 20 (4/20), aims to “flood” Instagram with anti-cannabis content. The DEA is offering monetary incentives to students for creating and posting anti-THC videos, with payments ranging from $25 to $50 depending on the type of content produced.

This approach has raised eyebrows, as it seems to contradict the growing acceptance and legalization of marijuana across the United States. Critics argue that such campaigns may be out of touch with current societal trends and scientific understanding of cannabis.



Source link

Continue Reading

Cannabis

How Hemp Helps You Sleep

Published

on

By


Not everyone has access to marijuana to help them sleep – good news, hemp is available.

it’s estimated 50 to 70 million Canadian and American adults experience sleep disorders or disturbances, and about one-third of adults don’t regularly get the recommended amount. Hemp has emerged as a promising natural remedy for those seeking better sleep. With its calming properties and potential to address various sleep-related issues, hemp-derived products are gaining popularity among individuals looking to improve their rest. Here is how hemp helps you sleep.

RELATED: Mike Johnson And Marijuana

Hemp contains several compounds contributing to better sleep quality. Cannabidiol (CBD), a non-psychoactive component of hemp, has shown potential in promoting relaxation and reducing anxiety, which can often interfere with a good night’s rest. Studies suggest that CBD may help individuals fall asleep faster and experience fewer sleep disturbances throughout the night.

When formulated and used properly, preliminary research and user reports suggest that hemp gummies improve subjective sleep quality. Users of quality hemp sleep gummies report feeling more rested, a better quality of sleep and fewer awakenings in the night. However, clinical research has shown that over consumption of THC negatively impacts the quality of sleep, especially with long term use.

Wana Brands has launched a hemp sleeping product nationally, Mike Hennesy, Vice President of Innovation shared the following about how it works. Naturally hemp-derived sleep gummies contain the same cannabinoids like CBD, CBN, and THC as cannabis or marijuana.  These ingredients interact with receptors in the body’s endocannabinoid system, which plays a role in regulating mood, stress, and sleep-wake cycles. For example, CBD may promote relaxation and reduce anxiety, CBN can relieve discomfort and reduce awakenings, while THC can shorten the time it takes to fall asleep, especially at low doses. Together, they may help ease the mind and body into a sleep-ready state.

The best sleep products don’t rely on just one cannabinoid like CBN but instead use a combination of cannabinoids, terpenes, and other sleep-supporting ingredients such as melatonin. This is because the reasons for sleeplessness are multifaceted, and include trouble falling asleep, staying asleep, chronic, pain and anxiety. Each ingredient targets different root causes as well as synergizes with the other cannabinoids and terpenes for the best night sleep.

Longer lasting formulations can actually help reduce awakenings in the night. CBN has been shown in recent research to reduce the number of times you wake up in the night. Combined with other cannabinoids they can synergize to reduce discomfort and anxiety helping consumers stay asleep.

RELATED: Marijuana Use And Guy’s Member

If you do wake up in the middle of the night and can’t fall back asleep products including CBD and CBG to reduce middle of the night anxiety and racing thoughts that can keep us awake, and they have only 1mg of THC so you wake up refreshed and not high in the morning.

For most people, hemp-derived cannabinoids are considered safe and non-intoxicating, with a low risk of dependence. When THC is included in small amounts, it can produce mild effects and can help us fall asleep faster. It generally poses a minimal risk when used in moderation, but there is a potential for dependence if overused, just like with any sleep aid. Adverse events are far more prevalent in pharmaceutical and even over the counter sleep aids than with hemp-derived cannabinoids.

The key is responsible use, including starting with a low dose and taking breaks when needed. If you rely on it every night at high doses, your body may adjust, and it can be habitual. But when used in moderation and with a well-balanced formula, cannabis can be a sustainable part of a healthy sleep routine.



Source link

Continue Reading

Burgundy

This Wine Issue Is Becoming More Common

Published

on

By


Wine is one of the popular drinks in the world, 

Roughly 75% of adults worldwide drink wine, with a significant portion consuming it regularly, and the US wine market sees a substantial number of people drinking wine and refining their taste. In fact, mearly half of adults (44%) drink at least a couple of glasses per week. But this wine issue is becoming more common, Charles Rice, Executive Director of the Wine Education Council shares the following.

RELATED: The Best Cocktails To Welcome Spring

Imagine attending a wine tasting, only to discover an unpleasant surprise with one of the bottle. It is bitter and even a little medicinal; it is starting and upsets the balance of the  really brings down the whole room and spoils what could have been a lovely evening. This uninvited guest is called ‘smoke taint’ and it a direct result of the increase in wildfires affecting many of the world’s top wine-growing regions. Let’s pour ourselves a glass and explore how this unwanted visitor is crashing the party and what the industry is doing to air out the room.

Smoke taint is like a bad hangover for grapes—it leaves them feeling a bit burned. When wildfires rage nearby, mature and growing grapes absorb volatile compounds, imparting an ashy, smoky flavor to the wine. It’s not just a surface issue: these compounds penetrate deep, forming glycosides that release their smokiness during fermentation. The result? Wines that taste more like a campfire or a doctor’s office than a sophisticated vintage. It’s a “grape” big disappointment!

Rising temperatures and changing weather patterns are fueling longer and more intense fire seasons. This means more frequent and severe wildfires, especially in regions like California, Oregon, and Australia—some of the world’s top wine-producing areas. The impact is twofold: not only do fires directly damage vineyards, but the smoke also compromises grape quality, leaving winemakers feeling crushed. It’s a drain on their passion, and their profits.

RELATED: 5 Weekend Habits To Adopt For A More Productive Week

Fortunately, researchers are working tirelessly to find ways to put a cork in the problem and coming up with some innovative solutions. Synthetic materials called ‘molecularly imprinted polymers’ can selectively remove smoky compounds from wine without stripping away desirable flavors and aromas. Activated carbon has been shown to be effective but can also remove some of the good stuff. It’s akin to using a broad-spectrum filter that catches both the smoke and some of the wine’s natural charm. Interestingly, producing sparkling wine from smoke-affected grapes is another creative workaround. The carbonation process can mask some of the smoky flavors, turning a potential loss into a bubbly opportunity. 

Smoke taint is undoubtedly uninvited guest when it comes to wine in the age of climate change, but the wine industry is not going to complain too much about sour grapes. With innovative solutions and a dash of creativity, winemakers are finding ways to keep the party going. So, the next time you sip a glass of wine, remember the uninvited guest that might have been there, but thanks to science and ingenuity, didn’t ruin the party. 



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media